Risankizumab is a Monoclonal Antibody owned by AbbVie, and is involved in 61 clinical trials, of which 39 were completed, 20 are ongoing, and 2 are planned.

Risankizumab (BI-655066) acts by neutralizing the p19 subunit of IL-23. Interleukin 23 (IL-23) is a heterodimeric cytokine composed of two disulfide-linked subunits, a p19 subunit that is unique to IL-23, and a p40 subunit that is shared with IL-12. The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. IL23 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). IL23 preferentially acts on memory CD4 (+) T cells. IL-23 induces proliferation and IFN-gamma production by human T cells. IL-23 is a key pro-inflammatory cytokine which can cause autoimmunity. IL-23 found to be highly expressed in psoriatic skin lesions, where it is mainly produced by tissue-resident and/or recruited dendritic cells (DCs).

The revenue for Risankizumab is expected to reach a total of $188bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Risankizumab NPV Report.

Risankizumab was originated by Boehringer Ingelheim International and is currently owned by AbbVie.

Risankizumab Overview

Risankizumab (Skyrizi) is a humanized monoclonal antibody, acts as an immunosuppressant agent. It is formulated as solution, concentrate solution for subcutaneous and intravenous route of administration. Skyrizi is indicated for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies. Skyrizi is indicated for: the treatment of adult patients with active psoriatic arthritis. Skyrizi can be used alone or in combination with a conventional non-biologic diseasemodifying antirheumatic drug (cDMARD) (e.g., methotrexate). Skyrizi is indicated for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies.

Risankizumab (BI-655066) is under development for the treatment of palmoplantar pustulosis, moderate to severe Crohn's disease, atopic dermatitis, ulcerative colitis and moderate to severe chronic plaque psoriasis with or without psoriatic arthritis, psoriatic erythroderma. BI-655066 is administered through subcutaneous and intravenous route. BI655066 is a humanized IgG1 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23. It was also under development for ankylosing spondylitis.

It was under development for the treatment of moderate to severe hidradenitis suppurativa, asthma and pustular psoriasis.

AbbVie Overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$56,197 million for the fiscal year ended December 2021 (FY2021), an increase of 22.7% over FY2020. In FY2021, the company’s operating margin was 31.9%, compared to an operating margin of 24.8% in FY2020. In FY2021, the company recorded a net margin of 20.5%, compared to a net margin of 10.1% in FY2020. The company reported revenues of US$14,812 million for the third quarter ended September 2022, an increase of 1.6% over the previous quarter.

Quick View – Risankizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Risankizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Musculoskeletal Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.